John Zhao

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.